introduct
moderatorsimon
glynn
md
mph
first
session
titl
bloodborn
infecti
agent
impact
blood
safeti
provid
stateofthesci
overview
risk
blood
safeti
pose
infecti
agent
addit
session
address
strategi
use
mitig
risk
unit
state
includ
introduct
increasingli
sensit
laboratori
screen
test
platform
prt
plt
plasma
product
first
part
session
includ
gener
overview
evolut
respons
establish
emerg
reemerg
transfusiontransmit
infecti
diseas
past
year
address
need
ongo
surveil
systemat
respons
emerg
infecti
diseas
eid
optim
sensit
metagenom
multiplex
nucleic
acid
amplif
technolog
nat
serolog
test
strategi
sentinel
global
donor
popul
follow
review
major
polici
issu
pertain
develop
implement
prt
success
adopt
provid
insur
known
unknown
pathogen
may
enter
blood
suppli
note
technolog
appli
blood
compon
wb
may
allow
relax
redund
donor
laboratori
screen
modifi
donor
question
andor
deferr
simplifi
handl
postdon
inform
preserv
enhanc
safeti
blood
suppli
session
end
overview
current
statu
approv
pathogenreduc
pr
plt
plasma
product
unit
state
attent
provid
current
effect
safeti
profil
major
reason
slow
adopt
current
approv
pr
product
unit
state
discuss
includ
costeffect
ce
consider
speaker
summari
blood
donor
screen
began
test
syphili
follow
earli
test
hepat
b
surfac
antigen
discoveri
human
immunodefici
viru
hiv
human
tlymphotrop
virus
hepat
c
viru
hcv
introduct
progress
sensit
serolog
assay
target
virusspecif
antibodi
antigen
classic
transfusiontransmit
infect
tti
effect
interdict
major
infecti
blood
donat
implement
nat
screen
hiv
hcv
hepat
b
viru
hbv
reduc
residu
risk
infecti
window
period
donat
perunit
risk
less
one
unit
state
fig
recogn
addit
classic
tti
establish
chronic
infect
agent
caus
acut
transient
infect
may
also
tti
signific
rate
larg
epidem
recurr
season
transmiss
salient
exampl
eid
intervent
implement
unit
state
includ
nationwid
screen
donor
trypanosoma
cruzi
use
onetim
antibodi
test
strategi
nat
test
west
nile
viru
wnv
zika
viru
zikv
test
babesia
microti
endem
region
test
bacteri
contamin
plt
compon
institut
prevent
septic
transfus
reaction
donor
deferr
also
implement
reduc
risk
includ
variant
creutzfeldtjakob
diseas
sever
agent
fig
list
eid
intervent
implement
past
two
decad
emerg
eid
proven
unpredict
risk
blood
safeti
eid
concern
span
pathogen
class
zoonot
sourc
aabb
develop
fact
sheet
avail
http
www
aabborgtmeidpagesdefaultaspx
provid
inform
agent
classif
background
pathogenesi
clinic
syndrom
mode
transmiss
includ
vectorsreservoir
likelihood
transfus
transmiss
tt
inform
known
transmiss
case
feasibl
predict
success
intervent
could
use
donor
qualif
question
test
avail
donor
screen
efficaci
prt
proactiv
surveil
research
evalu
respons
potenti
eid
threat
blood
safeti
adopt
collabor
initi
nih
fda
cdc
aabb
blood
research
organ
unintend
consequ
identif
agent
found
viral
discoveri
program
use
metagenom
technolog
theoret
transmit
transfus
upon
subsequ
investig
prove
fig
strike
exampl
xenotroph
murin
leukemiarel
viru
report
associ
prostat
cancer
later
chronic
fatigu
syndrom
present
blood
asymptomat
blood
donor
intens
research
consum
much
time
money
subsequ
determin
xenotroph
murin
leukemiarel
viru
affect
human
laboratori
contamin
cell
line
contain
murin
viru
experi
led
us
nation
heart
lung
blood
institut
nhlbi
fda
conven
workshop
focus
proactiv
ration
systemat
respons
eid
allianc
blood
oper
develop
riskbas
decisionmak
process
includ
formal
method
quantifi
risk
evalu
intervent
zikv
pandem
illustr
ongo
challeng
balanc
time
precautionari
respons
emerg
tti
threat
logist
econom
consider
epidem
expand
america
associ
zikv
sever
fetal
outcom
emerg
along
sever
case
probabl
tt
fda
mandat
implement
individualdon
id
nat
prt
plt
throughout
unit
state
year
idnat
low
yield
annual
cost
million
fda
zikv
polici
revis
allow
minipool
nat
idnat
trigger
futur
epidem
similar
success
screen
wnv
nonetheless
zikv
test
repres
theoret
benefit
high
cost
precipit
consider
region
screen
polici
urgent
need
defin
toler
risk
blood
safeti
arena
pathogen
reduct
overview
polici
issuesstev
kleinman
md
speaker
summari
pathogen
inactiv
andor
reduct
view
context
shift
blood
safeti
paradigm
reactiv
proactiv
therebi
provid
insur
known
unknown
pathogen
may
enter
blood
suppli
current
un
der
recogn
base
posit
experi
pi
plasma
deriv
eg
hiv
hcv
hbv
transmiss
sinc
seem
reason
appli
safeti
paradigm
blood
compon
note
consensu
confer
held
canada
issu
recommend
favor
rapid
adopt
pi
technolog
even
could
appli
full
rang
blood
compon
despit
recommend
pi
technolog
plt
slow
adopt
unit
state
describ
tabl
reason
mani
appear
predomin
impedi
cost
evalu
current
blood
safeti
risk
need
addit
intervent
import
understand
often
risk
express
perunit
basi
repres
likelihood
agent
surviv
storag
particular
type
blood
compon
eg
plasma
plt
rbc
risk
tt
agent
andor
occurr
symptomat
seriou
diseas
like
less
perunit
exposur
risk
hand
risk
estim
singleunit
transfus
risk
higher
ie
multipli
number
unit
major
patient
receiv
multipl
unit
either
singl
exposur
treatment
cours
assum
therapeut
product
efficaci
maintain
cost
issu
address
goal
blood
compon
rbc
plt
plasma
wb
compon
separ
treat
pithi
could
allow
relax
redund
donor
laboratori
screen
modif
donor
question
andor
deferr
simplifi
handl
postdon
inform
elimin
need
irradi
cellular
compon
prevent
transfusionassoci
graftversushost
diseas
tagvhd
potenti
blood
screen
chang
includ
elimin
syphili
cruzi
cytomegaloviru
cmv
babesia
test
modifi
menu
hbv
test
elimin
offseason
wnv
zikv
test
elimin
idnat
fulli
pitreat
blood
suppli
would
shape
respons
threat
new
enzym
immunoassay
would
less
pressur
develop
laboratori
screen
assay
addit
import
consider
evalu
role
pi
blood
safeti
polici
infecti
agent
inactiv
pi
technolog
nonenvelop
virus
prion
show
variabl
resist
manufactur
process
must
independ
evalu
quantit
level
inactiv
numer
known
pathogen
well
therapeut
efficaci
treat
compon
potenti
advers
effect
recipi
health
care
reimburs
system
must
also
abl
accommod
cost
current
statu
pathogenreduc
platelet
unit
statesedward
snyder
md
facp
sara
rutter
md
speaker
summari
pathogenreduc
plt
manufactur
use
synthet
psoralen
compound
amotosalen
approv
fda
use
patient
demograph
current
plt
pr
manufactur
system
approv
fda
unit
state
requir
ultraviolet
uv
light
activ
psoralen
photochem
enabl
function
inactiv
agent
approv
limit
singledonor
plt
collect
use
either
two
apheresi
devic
store
plt
addit
solut
pasc
autolog
donor
plasma
depend
apheresi
devic
use
manufactur
pr
product
shelf
life
c
psoralen
product
current
evalu
piper
phase
iv
postmarket
studi
manufactur
system
vari
degre
develop
one
system
use
differ
lightactiv
photochem
riboflavin
current
evalu
unit
state
phase
iii
random
clinic
trial
miplat
third
pr
technolog
use
shorter
wavelength
uv
light
uvc
sole
mechan
inactiv
evalu
captur
phase
iii
clinic
trial
europ
major
benefit
pr
plt
includ
multilog
inactiv
bloodborn
pathogen
inactiv
lymphocyt
thu
protect
tagvhd
despit
fda
approv
acknowledg
benefit
technolog
howev
medic
field
slow
adopt
integr
pr
technolog
daytoday
hospit
oper
reason
slow
adopt
includ
concern
possibl
mani
concern
address
publish
studi
importantli
clinic
report
shown
pr
plt
clinic
accept
fda
provid
draft
guidanc
date
agenc
stop
short
encourag
use
pr
technolog
thu
left
individu
hospit
whether
adopt
refrain
use
pr
plt
technolog
current
biggest
ongo
credibl
bloodborn
pathogen
threat
nation
blood
suppli
come
bacteri
contamin
pr
technolog
address
option
mitig
risk
bacteri
contamin
plt
includ
perform
secondari
bacteri
cultur
pointofreleas
immunolog
test
howev
new
viral
nonbacteri
agent
threaten
nation
blood
suppli
time
ramp
adequ
pr
manufactur
infrastructur
meet
nonbacteri
threat
would
like
substanti
widespread
adopt
pr
technolog
would
much
amelior
concern
scenario
overal
use
pr
technolog
slowli
increas
data
address
mani
abovelist
concern
report
least
abstract
form
howev
lack
extens
degre
publish
us
data
especi
pediatr
transplant
recipi
coupl
absenc
strong
fda
endors
technolog
high
cost
technolog
hamper
widespread
accept
pr
plt
possibl
anoth
bloodborn
threat
safeti
nation
blood
suppli
seem
inevit
well
mitig
threat
may
well
depend
issu
regard
pr
blood
product
resolv
critic
earli
adopt
pr
technolog
unit
state
publish
experi
util
pr
plt
patient
care
especi
pediatr
experi
pathogen
reduct
technolog
plasma
unit
statesjam
p
aubuchon
md
facp
frcp
edin
speaker
summari
two
method
pr
plasma
current
licens
avail
unit
state
solventdeterg
sd
treat
plasma
sd
plasma
octapla
octapharma
amotosalenuvtr
plasma
intercept
plasma
ceru
corpor
plasma
treat
riboflavin
uv
mirasol
plasma
terumo
bct
part
similar
system
develop
compon
also
includ
summari
techniqu
result
reduct
content
andor
activ
proand
anticoagul
protein
plasma
gener
reduct
exceed
mani
protein
reduct
less
notabl
reduct
fibrinogen
factor
f
viii
fv
across
platform
f
ix
fxi
protein
c
larg
von
willebrand
factor
multim
mirasol
protein
antiplasmin
octapla
investig
treatment
complement
compon
analysi
intercept
plasma
c
found
reduc
note
reduct
signific
usual
result
content
within
refer
rang
pool
natur
sd
plasma
greatli
reduc
variabl
content
easili
demonstr
differ
donor
plasma
sampl
cryoprecipit
may
prepar
intercept
mirasol
plasma
unit
meet
minimum
content
requir
although
effect
treatment
still
evid
vitro
analys
clot
system
gener
demonstr
substanti
retent
clinic
relev
function
might
expect
reduc
content
note
result
fibrin
strand
thinner
result
increas
clot
densiti
reduc
permeabl
longer
lag
time
format
prolong
time
lysi
multipl
clinic
trial
demonstr
expect
outcom
use
pr
plasma
sampl
prophylact
transfus
intercept
plasma
congenit
defici
patient
yield
expect
increas
defici
factor
circul
anticip
halfliv
use
larg
volum
intercept
plasma
plasma
exchang
thrombot
thrombocytopen
purpura
idiopath
thrombocytopen
purpura
result
expect
outcom
without
gener
advers
event
new
coagulopathi
use
larg
volum
approx
l
intercept
plasma
liver
transplant
yield
outcom
quarantin
plasma
current
formul
octapla
report
associ
thrombot
event
use
larg
volum
seen
origin
version
sd
plasma
theoret
question
rais
whether
reduc
content
compon
might
place
massiv
transfus
recipi
increas
risk
inadequ
hemostasi
death
one
vitro
mix
studi
suggest
plasma
replac
would
necessari
alter
coagul
kinet
sever
larg
histor
control
experi
intercept
plasma
trauma
situat
howev
fail
show
impact
need
blood
compon
time
discharg
mortal
pr
plasma
sampl
associ
increas
advers
event
transfus
pool
basi
sd
plasma
believ
carri
reduc
risk
transfusionrel
acut
lung
injuri
trali
dilut
potenti
offend
antibodi
trali
case
report
million
octapla
unit
transfus
exist
risk
trali
greater
one
remov
risk
make
use
sd
plasma
costeffect
pool
howev
increas
risk
earli
wide
dissemin
nascent
nonenvelop
viru
date
littl
uptak
pr
plasma
unit
state
outsid
octapla
patient
sever
allerg
reaction
singledonor
plasma
probabl
due
percept
viral
safeti
lack
bacteri
contamin
risk
standard
plasma
increas
cost
newer
plasma
widespread
introduct
like
follow
implement
similar
system
plt
rbc
despit
admonish
consensu
confer
demonstr
import
plasma
transmiss
new
pathogen
experi
nation
largest
blood
product
supplier
blood
bank
nih
clinic
center
document
report
stress
relev
strict
volum
cell
limit
requir
without
prt
effect
collect
procedur
failur
approach
almost
diametr
oppos
reflect
differ
donor
set
american
red
cross
prefer
smallvolum
largevolum
kit
vs
nih
blood
bank
exclus
use
dualstorag
kit
american
red
cross
boost
prt
plt
meet
steadili
increas
demand
nih
blood
bank
transit
prt
plt
product
well
receiv
attend
physician
nurs
qualiti
variabl
expect
chang
prt
affect
treat
cell
risk
must
monitor
balanc
technolog
prt
plt
addit
solut
pa
continu
evolv
prt
plasma
individu
donor
although
fdalicens
devic
avail
introduc
patient
care
end
similar
lyophil
plasma
avail
singledonor
sourc
prt
plasma
altern
pool
mani
donor
exist
sdtreat
plasma
histori
worldwid
use
sinc
five
random
control
trial
show
differ
efficaci
trial
size
rang
patient
total
patient
trali
report
passiv
collect
data
may
reflect
incid
costeffect
estim
prt
plt
plasma
report
product
consid
less
costeffect
wide
adopt
intervent
context
blood
safeti
technolog
budget
gap
like
remain
prt
becom
avail
wb
rbc
lowand
middleincom
countri
may
requir
mix
approach
need
assess
target
intervent
prt
plt
implement
nationwid
countri
effort
improv
patient
safeti
reimburs
note
key
factor
unit
state
stall
quicker
implement
prt
plt
plasma
transfus
signific
challeng
initi
experi
limit
percentag
plt
collect
elig
pi
base
approv
guard
band
also
goal
harm
plt
suppli
due
grow
demand
singledonor
plt
convert
tripl
doubl
doubl
singl
qualifi
pi
final
licens
intercept
kit
pa
tripl
yet
exist
initi
perform
guard
band
unsatisfactori
apheresi
plt
produc
red
cross
tripl
leav
doubl
singl
qualifi
singleand
doubleplateletpheresi
unit
fail
nativ
meet
pi
input
requir
target
program
set
point
maxim
yield
collect
devic
default
valu
firsttim
donor
red
cross
initi
evalu
mitig
strategi
design
increas
percentag
unit
qualifi
pi
volum
reduct
deploy
remov
product
volum
homogen
mixtur
amicuspa
apheresi
plt
meet
intercept
guard
band
red
cross
develop
valid
softwar
tool
aid
staff
select
option
volum
reduct
addit
mitig
develop
advanc
intercept
tripl
kit
staff
split
tripl
collect
three
individu
storag
contain
prt
use
singl
smallvolum
largevolum
intercept
kit
treat
product
individu
largevolum
doubl
may
split
two
smallvolum
largevolum
kit
collect
team
adjust
amicu
set
optim
storag
volum
ml
doubl
ml
tripl
includ
minimum
volum
buffer
minimum
plt
yield
approxim
plt
product
met
guard
band
oper
trial
presplit
larg
obviat
need
conduct
volum
reduct
number
pr
unit
current
label
less
due
combin
demand
staf
aggreg
unit
exceed
hour
addit
observ
includ
radic
shift
type
pi
kit
use
predominantli
dualstorag
kit
smallvolum
kit
use
largevolum
kit
remain
implement
mitig
split
rate
pi
product
fell
implement
mitig
split
rate
pi
product
increas
program
amicu
devic
standard
collect
volum
increas
tripl
becam
elig
product
downgrad
labor
requir
prt
greater
use
bactalert
system
singl
bottl
time
studi
compar
process
demonstr
increas
time
requir
complet
task
unmitig
pi
product
compar
tradit
process
increas
time
requir
complet
task
mitig
pi
product
compar
tradit
process
product
unmitig
pi
process
poor
volum
product
elig
treatment
low
batch
size
two
four
product
product
improv
implement
mitig
step
due
signific
increas
product
elig
treatment
increas
batch
size
eight
product
pathogen
reduct
product
challeng
imposs
base
current
guard
band
mitig
requir
meet
guard
band
feasibl
laborintens
timeconsum
implement
prt
requir
adjust
set
point
collect
variabl
apheresi
devic
speaker
summari
nih
clinic
center
nation
institut
health
nation
largest
hospit
devot
entir
clinic
research
approxim
studi
progress
focus
phase
ii
clinic
trial
depart
transfus
medicin
fullservic
blood
bank
provid
blood
donat
clinic
apheresi
transfus
servic
human
leukocyt
antigen
hla
infecti
diseas
test
hospit
cellular
engin
support
cell
therapi
transfus
plt
rbc
plasma
granulocyt
product
patient
blood
compon
gy
irradi
rbc
product
also
leukoreduc
sinc
none
transfus
older
day
sinc
transit
pr
plt
collect
apheresi
pa
januari
within
month
devic
approv
fda
nih
clinic
center
decid
januari
implement
prt
concurr
pa
plt
product
final
bring
longanticip
technolog
bedsid
unit
state
retrospect
evalu
success
collect
month
earli
show
collect
met
guard
band
specifi
prt
fell
within
guard
band
prt
dualstorag
kit
decid
exclus
use
kit
prepar
adjust
variabl
approxim
collect
meet
guard
band
specif
success
anticip
loss
less
collect
due
failur
meet
guard
band
agreement
devic
provid
sign
intercept
ceru
corpor
intersol
freseniu
kabi
initi
task
implement
team
involv
write
valid
plan
standard
oper
procedur
order
instal
valid
requir
equip
reconfigur
space
hous
equip
fit
new
work
flow
comput
upgrad
accommod
chang
made
juli
train
prt
began
august
pa
septemb
adjust
collect
variabl
valid
prt
pa
process
continu
next
month
first
apheresi
plt
product
prt
pa
releas
januari
dual
inventori
plt
produc
new
previou
process
last
less
week
promptli
transit
plt
collect
prt
pa
fine
tune
collect
variabl
critic
need
monitor
maintain
continu
remain
ongo
task
donor
staff
plt
collect
close
origin
goal
less
guard
band
failur
tabl
produc
prt
plt
plateletpheresi
collect
nih
clinic
center
bridg
shortag
suppli
serv
patient
rare
hla
antibodi
must
import
plt
remain
almost
invari
produc
without
prt
irradi
gy
requir
enter
inventori
releas
patient
provid
bacteri
test
upon
releas
retir
previou
precaut
prevent
bacteri
contamin
ml
sampl
within
hour
collect
releas
inventori
hour
neg
cultur
singl
standard
aerob
bottl
bactec
becton
dickinson
co
monitor
cultur
day
prt
product
elimin
irradi
possibl
without
varianc
notif
sinc
march
bacteri
cultur
result
substanti
save
consum
handl
howev
exceed
cost
new
technolog
increas
handson
time
product
staff
report
transfus
reaction
rang
nine
annual
without
discern
trend
certainli
increas
sever
transfus
reaction
occur
educ
notif
import
accept
hospit
staff
within
week
first
new
product
releas
transfus
notifi
sever
extern
custom
provid
revis
circular
inform
call
receiv
prescrib
nih
clinic
center
inform
offic
deputi
director
clinic
care
focu
improv
patient
safeti
call
nurs
staff
inform
nurs
educ
leadership
provid
photo
current
versu
new
bag
highlight
lack
irradi
label
new
bag
explain
new
electron
transfus
document
institut
reluct
introduc
prt
plt
neonat
children
pregnant
women
theoret
risk
associ
toxic
psoralen
photo
product
evid
date
dose
appli
concern
rais
nih
exampl
cost
increas
justifi
abat
zikv
occur
continent
unit
state
prt
plt
recogn
safe
without
action
need
ongo
task
improv
prompt
avail
predon
plt
count
better
control
collect
process
reduc
guard
band
failur
optim
report
document
pursuit
biolog
licens
applic
fdacber
permiss
eventu
ship
biolog
product
across
state
line
mani
patient
depend
plt
transfus
qualiti
life
plt
prt
pa
enabl
us
enhanc
patient
safeti
impact
pathogen
reduct
technolog
platelet
qualiti
count
clinic
implic
speaker
summari
laboratori
investig
pitreat
plt
compon
readili
show
approach
use
gener
chang
vitro
qualiti
variabl
expect
result
pi
treatment
specif
pathogen
human
cell
also
target
process
alon
caus
loss
plt
step
involv
transfer
plt
concentr
treatment
bag
transfer
back
storag
bag
case
plt
count
reduct
typic
product
plan
must
accommod
loss
treat
plt
show
evid
activ
loss
variou
rna
speci
acceler
decreas
ph
storag
pi
treatment
may
also
caus
releas
plt
cytokin
includ
egf
pdgf
rant
overal
use
pi
andor
reduct
technolog
result
plt
respons
interpret
reduct
plt
product
qualiti
laboratori
test
unclear
whether
use
best
test
perform
qualiti
monitor
pr
plt
use
untreat
plt
result
vitro
laboratori
marker
presum
parallel
clinic
efficaci
pitreat
transfus
product
pr
plt
show
decreas
surviv
recoveri
normal
volunt
surprisingli
translat
shorter
intertransfus
interv
patient
receiv
prophylact
transfus
product
unlik
anim
model
patient
treat
pi
plt
increas
risk
alloimmun
reason
yet
determin
importantli
studi
hematolog
oncolog
patient
reveal
increas
risk
bleed
use
pitreat
plt
although
use
may
confound
factor
differ
compar
transfus
untreat
plt
tradeoff
increas
safeti
still
unknown
respect
use
pitreat
plt
activ
bleed
patient
particularli
massiv
hemorrhag
whether
use
larg
volum
pitreat
product
includ
pitreat
plt
amplifi
neg
effect
pi
plt
efficaci
overal
hemostasi
remain
determin
limit
retrospect
studi
surgic
patient
given
caus
alarm
respect
advers
reaction
efficaci
import
research
question
remain
answer
develop
strategi
minim
damag
plt
rbc
includ
use
better
ass
storag
condit
retent
rate
platelet
prt
process
mean
ae
standard
deviat
number
prt
platelet
product
test
qualiti
assur
document
loss
platelet
na
applic
treatment
best
qualiti
control
measur
pi
plt
use
multipl
type
pitreat
product
trauma
realli
creat
problem
need
assess
clinic
howev
studi
expens
take
long
time
complet
need
adapt
transfus
practic
accommod
pitreat
product
may
particularli
import
pediatr
patient
best
calcul
risk
benefit
pi
expens
technolog
may
result
increas
plt
use
must
remind
pi
cellular
product
major
paradigm
shift
transfus
safeti
system
current
avail
first
gener
certainli
see
improv
time
minim
neg
side
balanc
sheet
use
solventdetergenttr
pool
plasma
octapla
implement
univers
minnesotaclaudia
cohn
md
phd
speaker
summari
octapla
fdaapprov
blood
compon
sdtreat
plasma
manufactur
combin
multipl
abomatch
plasma
unit
healthi
us
donor
plasma
unit
frozen
within
hour
collect
pool
approx
l
donor
unit
state
filter
remov
residu
cell
treat
combin
tri
nbutyl
phosphat
octoxynol
inactiv
envelop
virus
residu
sd
remov
oil
extract
chromatographi
final
product
sterilefilt
aliquot
bag
store
frozen
octapla
indic
replac
coagul
factor
patient
acquir
defici
due
liver
diseas
undergo
cardiac
surgeri
liver
transplant
plasma
exchang
patient
thrombot
thrombocytopen
purpura
octapla
contraind
patient
immunoglobulin
defici
sever
defici
protein
contraind
includ
histori
hypersensit
freshfrozen
plasma
andor
plasmaderiv
product
common
convent
plasma
compon
octapla
may
store
three
year
c
thaw
octapla
may
store
hour
c
hour
room
temperatur
plasma
use
make
octapla
test
viral
marker
complianc
us
regul
howev
addit
step
mitig
risk
infecti
diseas
transmiss
sd
treatment
inactiv
envelop
virus
logkil
reduct
factor
least
common
virus
hiv
hbv
hcvc
wnv
zikv
dengu
viru
addit
test
perform
nonenvelop
virus
pool
plasma
may
contain
parvoviru
dna
must
neg
hepat
viru
hav
nat
polymeras
chain
reaction
pcr
hepat
e
viru
hev
rna
nat
pcr
sensit
log
iuml
furthermor
octapla
contain
prespecifi
level
neutral
antibodi
hav
parvoviru
final
steril
filtrat
step
could
remov
addit
infecti
agent
pool
ad
benefit
dilut
allergen
approxim
reduc
risk
allerg
reaction
multipl
studi
shown
compar
reduct
rate
allerg
reaction
tabl
pool
like
mitig
risk
trali
dilut
neutral
antibodi
human
neutrophil
antigen
hla
sd
process
also
remov
bioactiv
lipid
implic
caus
factor
trali
prove
neg
imposs
million
unit
octapla
transfus
zero
incid
trali
report
level
coagul
factor
proteas
inhibitor
cofactor
test
lot
releas
older
version
sd
plasma
associ
hyperfibrinolysi
bleed
howev
chang
manufactur
process
mitig
risk
advers
event
sever
studi
conduct
current
version
octapla
addit
risk
advers
event
identifi
clinic
relev
differ
efficaci
identifi
howev
studi
small
may
power
show
signific
differ
univers
minnesota
chosen
maintain
inventori
octapla
patient
histori
moder
sever
allerg
transfus
reaction
especi
help
patient
undergo
plasma
exchang
must
contend
multipl
unit
convent
plasma
extra
time
effort
save
reduct
reaction
plu
increas
comfort
safeti
experienc
patient
make
ad
cost
octapla
worthwhil
conclus
efficaci
safeti
profil
octapla
make
good
altern
convent
plasma
benefici
patient
histori
allerg
transfus
reaction
speaker
summari
pathogen
reduct
technolog
must
evalu
two
differ
health
econom
bia
type
cost
account
studi
focus
implement
mainten
health
care
intervent
rel
short
period
time
typic
year
cea
assess
ratio
cost
benefit
compar
least
two
differ
intervent
result
often
report
cost
per
qualityadjust
lifeyear
qali
ce
plane
use
graphic
display
result
cea
separ
cost
effect
way
provid
sever
insight
rel
effici
intervent
includ
analysi
thu
highli
inform
broader
decis
make
process
prt
health
econom
prt
unit
state
continu
one
barrier
broader
adopt
prt
sever
technolog
differ
mechan
action
inactiv
capac
review
detail
sever
previou
public
differ
import
health
econom
technolog
although
rbc
inactiv
wb
inactiv
technolog
develop
clinic
studi
way
current
health
econom
evid
publish
method
two
prt
sdtreat
plasma
amotosalen
plu
uv
light
plt
plasma
approv
use
unit
state
exemplari
combin
bia
cea
conduct
canadian
agenc
drug
technolog
health
report
howev
health
econom
plt
prt
arguabl
import
defin
bia
cea
plt
highli
depend
level
clinic
appar
bacteri
contamin
plt
prepar
method
use
given
set
recent
publish
bia
focus
analysi
midsiz
us
hospit
assum
acquir
apheresi
plt
compon
per
year
extern
blood
supplier
sever
assumpt
analysi
sought
mimic
realist
situat
assum
approxim
acquir
plt
irradi
test
cmv
blood
supplier
model
predict
minim
cost
increas
prt
compar
convent
plt
includ
cost
offset
elimin
bacteri
detect
irradi
differenti
reimburs
treat
untreat
plt
anoth
bia
conduct
itali
conclud
studi
base
actual
number
plt
transfus
complic
societ
cost
local
level
need
establish
full
cost
benefit
ratio
plt
prt
sever
studi
examin
costeffect
plasma
prt
compar
benchmark
health
care
ce
result
plasma
prt
expect
fall
rang
regardless
technolog
ce
plt
prt
variabl
without
remov
bacteri
cultur
use
hemovigil
data
estim
report
bacteri
contamin
whether
lead
clinic
appar
sepsi
consid
cultur
discontinu
result
might
approach
ce
prt
plt
plasma
addit
current
intervent
estim
approxim
cost
offset
might
feasibl
discontinu
intervent
use
alongsid
cost
implement
need
consid
jointli
part
valu
proposit
prt
emerg
agent
potenti
shift
ratio
costeffect
may
approach
accept
threshold
health
care
analys
focus
cost
offset
achiev
publish
expect
increas
near
futur
reimburs
also
barrier
adopt
assess
budget
impact
ce
pathway
reimburs
prt
necessari
consider
success
widespread
use
prt
introduct
moderatorraymond
p
goodrich
phd
technolog
treatment
blood
product
prevent
tt
diseas
develop
year
review
issu
associ
technolog
consid
hypothet
framework
rather
context
experi
observ
use
routin
product
plt
plasma
product
knowledg
may
also
extrapol
ongo
develop
effort
method
treatment
wb
rbc
product
main
topic
present
section
workshop
recent
develop
focus
use
prt
method
modifi
method
use
nonlightactiv
chemistri
treat
either
wb
rbc
compon
separ
wb
sever
product
clinic
phase
evalu
challeng
face
expect
compar
experienc
broadli
approv
implement
method
treat
plt
plasma
ad
complic
challeng
due
number
unit
requir
treat
natur
patient
receiv
rbc
product
compar
plt
plasma
compon
session
intend
discuss
histor
experi
prt
method
provid
overview
latest
inform
avail
develop
method
produc
wb
rbc
product
treat
prt
method
optim
pathogen
reduct
system
blood
safeti
dream
raymond
p
goodrich
phd
colorado
state
univers
co
speaker
summari
experi
implement
prt
method
plt
plasma
lesson
teach
us
extend
applic
process
product
wb
rbc
product
measur
reduct
cell
protein
qualiti
treatment
preclin
studi
clinic
trial
prt
conduct
preced
year
repeatedli
demonstr
chang
vitro
vivo
variabl
includ
chang
metabol
variabl
treat
plt
chang
aggreg
adhes
function
chang
plt
proteom
metabolom
measur
similar
result
plasma
product
shown
reduc
coagul
factor
level
treatment
clinic
studi
evalu
perform
product
demonstr
noninferior
regard
prevent
bleed
patient
hematolog
malign
estcourt
colleagu
summar
metaanalys
clinic
trial
product
indic
found
moderatequ
evid
pathogenreduc
platelet
transfus
affect
allcaus
mortal
risk
clinic
signific
sever
bleed
risk
seriou
advers
event
author
also
note
found
highqual
evid
pathogenreduc
platelet
transfus
increas
risk
platelet
refractori
platelet
transfus
requir
addit
ad
blood
suppli
common
blood
addit
routin
present
human
bodi
prt
method
implement
approv
use
unit
state
outsid
unit
state
base
use
chemic
addit
blood
product
activ
specif
way
prevent
nucleic
acid
replic
target
pathogen
white
blood
cell
wbc
product
natur
compound
use
approach
vari
consider
base
method
includ
use
riboflavin
vitamin
well
synthet
deriv
compound
amotosalen
amustalin
base
psoralen
acridin
mustard
hydrochlorid
deriv
respect
mani
case
agent
breakdown
product
exhibit
consider
toxic
genotox
must
consid
term
like
patient
popul
effect
handl
remov
method
intend
reduc
exposur
patient
health
care
worker
process
requir
necessit
natur
agent
use
complic
practic
logist
deliv
blood
product
patient
pathogen
elimin
applic
process
variabl
level
pr
observ
bacteria
envelop
virus
depend
method
appli
knowledg
level
inactiv
necessari
prevent
diseas
transmiss
clear
uniform
agent
exampl
avail
complet
ongo
routin
use
studi
suggest
diseas
transmiss
may
significantli
curtail
breakthrough
event
may
still
anticip
includ
case
pathogen
load
donat
product
may
exceed
inactiv
potenti
prt
method
may
prove
ineffect
specif
type
resist
agent
nonenvelop
virus
method
deliv
outcom
pathogen
load
reduct
capabl
henc
continu
field
evalu
need
significantli
reduc
probabl
diseas
transmiss
area
diseas
endem
necessari
fulli
determin
extent
effect
process
control
essenti
assur
reproduc
reliabl
method
signific
effort
made
manufactur
develop
techniqu
practic
appli
treatment
plt
plasma
product
routin
blood
bank
set
devic
process
need
account
practic
factor
includ
throughput
product
specif
media
product
loss
time
process
step
record
keep
cost
manufactur
dispos
equip
valid
method
requir
signific
invest
part
manufactur
yet
concern
categori
relat
implement
remain
continu
identifi
method
enter
routin
clinic
use
process
add
cost
routin
implement
highincom
countri
endem
diseas
exposur
rare
like
continu
debat
basi
cost
benefit
advanc
adopt
like
result
process
serv
lowincom
nation
signific
blood
safeti
concern
afford
product
made
high
qualiti
low
cost
question
implement
patient
vulner
thu
may
benefit
method
need
ask
group
may
includ
receiv
chronic
transfus
support
pediatr
patient
costbenefit
riskbenefit
calcul
like
favor
outcom
provid
product
region
high
endem
diseas
rate
greatli
improv
costbenefit
analys
requir
partnership
nongovernment
organ
longerterm
consider
sustain
environ
supplement
cost
longer
feasibl
clinic
experi
pathogen
reduct
red
blood
cell
complet
triadrichard
j
benjamin
md
phd
frcpath
speaker
summari
uniqu
technolog
need
adequ
balanc
need
robust
broadspectrum
pi
dispar
characterist
rbc
plt
plasma
protein
intercept
rbc
incorpor
treatment
rbc
mmoll
amustalin
presenc
mmoll
glutathion
gsh
close
system
amustalin
rapidli
crosslink
andor
form
adduct
nucleic
acid
prevent
pathogen
replic
without
gener
reactiv
oxygen
speci
ro
activ
compound
degrad
undetect
concentr
nmoll
process
exchang
step
licens
storag
solut
remov
major
breakdown
product
result
treat
rbc
shelf
life
extens
test
confirm
lack
neonat
reproduct
toxic
carcinogen
genotox
acut
chronic
toxic
confirm
potent
inactiv
broad
rang
envelop
nonenvelop
virus
bacteria
protozoa
wbc
anim
model
confirm
lack
immunogen
treat
rbc
demonstr
reduc
hemolysi
increas
atp
level
compar
convent
irradi
rbc
similar
closedsystem
process
develop
wb
collect
collabor
swiss
red
cross
use
auster
environ
intercept
rbc
success
evalu
seri
clinic
trial
demonstr
safeti
efficaci
perform
system
tabl
radiolabel
recoveri
surviv
studi
healthi
volunt
confirm
accept
rbc
recoveri
life
span
exceed
fda
requir
phase
iii
random
control
studi
star
involv
complex
cardiac
surgeri
patient
germani
demonstr
treat
rbc
met
predetermin
noninferior
margin
hemoglobin
hb
content
mean
treatment
differ
testcontrol
gunit
ci
gunit
within
prespecifi
equival
margin
gunit
reduc
hemolysi
end
storag
subject
receiv
mean
rang
test
control
rbc
compon
surgeri
within
day
surgeri
exploratori
clinic
endpoint
includ
renal
hepat
insuffici
walk
test
well
advers
event
differ
patient
antibodi
specif
intercept
rbc
second
random
doubleblind
control
crossov
studi
sparc
perform
itali
turkey
complet
transfusiondepend
thalassemia
patient
receiv
regular
rbc
transfus
treat
anemia
suppress
ineffect
hematopoiesi
tabl
patient
year
old
receiv
six
cycl
two
washin
four
efficaci
evalu
cycl
test
control
rbc
rbc
dose
determin
physician
blind
treatment
primari
endpoint
hb
consumpt
g
hbkgday
measur
iron
burden
subject
met
predetermin
noninferior
margin
control
hb
consumpt
intent
treat
perprotocol
popul
receiv
mean
test
control
rbc
two
treatment
period
rbc
compon
transfus
protocol
six
patient
advers
event
similarli
distribut
period
patient
made
treatmentemerg
antibodi
intercept
rbc
rbc
alloantigen
complet
studi
demonstr
safeti
efficaci
intercept
rbc
vitro
analys
demonstr
robust
pi
us
clinic
studi
cardiac
surgeri
recepi
gener
hospit
popul
rede
way
see
clinicaltrialsgov
avail
prt
rbc
plt
plasma
would
increas
patient
safeti
revolution
current
reactiv
increment
test
approach
infecti
diseas
threat
may
also
allow
reassess
need
current
donor
deferr
test
requir
speaker
summari
mirasol
prt
system
ce
mark
treatment
plt
plasma
wb
transfus
routin
use
mani
countri
outsid
unit
state
mirasol
prt
system
use
one
devic
treat
blood
product
mirasol
consist
photosensit
riboflavin
vitamin
combin
uv
light
irrevers
damag
dna
rna
result
inactiv
virus
bacteria
parasit
wbc
riboflavin
photoproduct
nontox
natur
occur
requir
remov
blood
product
treatment
wb
mirasol
program
develop
partnership
us
depart
defens
dod
african
investig
mirasol
system
aim
clinic
trial
komfo
anoky
teach
hospit
kumasi
ghana
first
clinic
trial
demonstr
prt
effect
reduc
incid
tti
bloodborn
pathogen
test
arm
consist
mirasoltr
nonleukoreduc
wb
control
arm
consist
untreat
nonleukoreduc
wb
sixtyf
nonparasitem
patient
expos
parasitem
blood
receiv
mirasoltr
wb
receiv
untreat
wb
incid
transfusiontransmit
malaria
significantli
lower
patient
receiv
mirasoltr
wb
one
patient
compar
patient
receiv
untreat
wb
eight
patient
p
moreov
signific
differ
total
hb
day
posttransfus
advers
event
mirasoltr
wb
untreat
wb
success
aim
clinic
trial
support
ce
mark
mirasol
prt
system
treatment
wb
transfus
complet
aim
clinic
trial
japan
intern
cooper
agenc
partner
terumo
corpor
japan
aabb
consult
servic
support
sustain
blood
safeti
ghana
routin
use
mirasol
wb
system
conjunct
creation
infrastructur
hemovigil
system
partnership
expand
use
mirasol
prt
wb
within
ghana
establish
activ
hemovigil
system
two
teach
hospit
komfo
anoky
teach
hospit
kumasi
korlebu
teach
hospit
accra
provid
necessari
train
support
septemb
japan
intern
cooper
agenc
success
hand
ghana
blood
safeti
program
ministri
health
moh
dr
aaron
tobian
makerer
universityjohn
hopkin
univers
mujhu
collabor
expand
use
mirasol
prt
system
wb
africa
uganda
mirasol
evalu
reduct
infect
trial
merit
primari
object
evalu
mirasol
wb
system
reduc
malaria
tti
uganda
secondari
object
includ
evalu
impact
tti
potenti
benefit
prt
well
feasibl
sustain
implement
mirasol
auster
environ
addit
mirasol
prt
treatment
wb
transfus
activ
studi
way
evalu
component
mirasoltr
wb
terumo
bct
initi
prais
clinic
trial
evalu
efficaci
safeti
rbc
deriv
mirasoltr
wb
compar
convent
rbc
patient
requir
chronic
transfus
support
moreov
terumo
bct
support
investigatoriniti
studi
compon
deriv
mirasoltr
wb
one
studi
conduct
dr
pavel
trakhtman
russian
feder
center
pediatr
hematolog
oncolog
immunolog
evalu
safeti
efficaci
rbc
deriv
mirasoltr
wb
pediatr
patient
malign
final
part
terumo
bct
commit
advanc
blood
safeti
compani
invest
innov
refin
improv
prt
pathogen
reduct
technolog
red
blood
cell
product
impact
biochem
viabil
variabl
humansjos
cancela
md
phd
speaker
summari
despit
implement
improv
diagnost
screen
donor
select
residu
risk
transmiss
new
emerg
pathogen
bacteri
contamin
persist
pr
blood
compon
may
capabl
proactiv
reduc
andor
elimin
chanc
diseas
transmiss
transfus
pr
could
replac
current
paradigm
serial
introduct
diagnost
test
new
microorgan
potenti
tt
recogn
pr
rbc
wb
product
remain
major
challeng
develop
safe
blood
product
transfus
major
interest
context
chronic
transfus
protocol
first
technolog
evalu
use
riboflavinuv
jml
rbc
light
mirasol
system
pr
wb
riboflavinuv
light
pr
technolog
mirasol
prt
system
mirasol
method
base
irrevers
nucleic
acid
damag
mediat
electron
transfer
process
site
riboflavinguanin
base
chemistri
occur
group
other
alreadi
publish
signific
inform
rbc
viabil
pr
wbderiv
rbc
vitro
context
highdos
illumin
result
signific
pr
set
data
indic
pr
wb
possibl
albeit
loss
rbc
viabil
vitro
assess
hemolysi
atp
level
potassium
leakag
vivo
assess
recoveri
surviv
analys
twocent
clinic
trial
combin
data
consist
support
riboflavinuv
lighttreat
rbc
store
day
gener
mirasoltr
wb
maintain
adequ
level
recoveri
assess
crtag
circulatori
rbc
surviv
analysi
anticip
decreas
vivo
viabil
poststorag
riboflavinuv
light
rbc
compar
data
obtain
donor
similarli
store
untreat
rbc
overal
recoveri
surviv
area
curv
auc
mirasol
rbc
reduc
respect
compar
subject
untreat
control
rbc
expect
percentag
rbc
hemolysi
significantli
correl
recoveri
control
rbc
surviv
suggest
hemolysi
recoveri
measur
destruct
popul
cell
surviv
storag
contrast
similar
correl
percent
hemolysi
recoveri
mirasol
rbc
percent
hemolysi
howev
mirasol
rbc
signific
correl
atp
level
recoveri
similar
associ
found
control
rbc
second
technolog
test
prt
use
amustalin
approach
target
nucleic
acidcontain
pathogen
requir
photochem
activ
use
small
molecul
amustalin
react
rapidli
nucleic
acid
decompos
unreact
byproduct
publish
pi
result
show
amustalin
treatment
rbc
effect
inactiv
multipl
bloodborn
pathogen
log
residu
wbc
prevent
nonspecif
reaction
amustalin
rbc
membran
protein
gsh
use
conjunct
amustalin
treatment
two
differ
twocent
studi
analyz
viabil
rbc
prepar
secondgener
process
store
day
evalu
two
differ
blood
center
phase
ii
clinic
trial
design
respect
singleblind
random
control
twoperiod
crossov
studi
amustalin
control
rbc
prepar
random
sequenc
store
day
follow
cr
tag
rbc
posttransfus
recoveri
mean
life
span
median
lifespan
life
span
auc
analyz
mean
posttransfus
recoveri
test
control
rbc
compar
ae
ae
respect
p
consist
fda
criteria
accept
rbc
viabil
differ
test
control
rbc
day
differ
p
within
publish
refer
rang
day
auc
percent
surviv
day
test
control
rbc
similar
surviv
cell
day
respect
p
infus
test
rbc
clinic
relev
abnorm
laboratori
valu
advers
event
technolog
repres
exampl
firstgener
effort
toward
develop
technolog
maintain
product
potenc
erad
nucleic
acidcontain
pathogen
goal
increas
safeti
tradeoff
reduct
rbc
result
provid
indic
potenc
rbc
treat
pr
product
especi
riboflavinuv
light
would
fall
short
goal
believ
result
may
form
part
basi
discuss
develop
improv
protocol
andor
approach
pr
wb
gener
specif
rbc
nucleic
acidbind
photosensit
flexibl
structur
pathogen
inactiv
red
blood
cell
suspensionsstephen
j
wagner
phd
speaker
summari
photochem
local
nucleic
acid
target
site
well
offtarget
locat
supernat
bound
rbc
plt
upon
illumin
photochem
bound
target
produc
singlet
oxygen
ro
involv
electron
transfer
adduct
format
prevent
replic
pathogen
photochem
local
supernat
produc
ro
diffus
plt
rbc
membran
produc
oxid
damag
undergo
electron
transfer
coloc
photochem
produc
photochem
dimer
photochem
bound
rbc
plt
membran
produc
ro
oxid
membran
compon
produc
coval
adduct
polyunsatur
lipid
via
electron
transfer
offtarget
lesion
respons
alter
vitro
vivo
properti
photochem
treat
rbc
plt
photochem
compos
fuse
ring
conjug
doubl
bond
photochem
absorb
light
dissip
absorb
energi
via
bond
rotat
heat
rigid
ring
structur
therefor
releas
energi
via
fluoresc
phosphoresc
photochem
reaction
hand
flexibl
photosensit
dissip
absorb
light
energi
bond
rotat
therefor
readili
act
photochem
unless
rigidli
bound
substrat
planar
geometri
one
flexibl
dye
thiazol
orang
bind
minor
groov
nucleic
acid
act
photochem
bound
particip
photochem
reaction
free
solut
use
thiazol
orang
rbc
suspend
erythrosol
jcm
cool
white
light
result
inactiv
log
vesicular
stomat
viru
log
bovin
viru
diarrhea
viru
log
pseudorabi
viru
log
extracellular
hiv
log
intracellular
hiv
log
leishmania
donavani
infantum
log
cruzi
bacteri
inactiv
rang
log
depend
speci
rbc
storag
studi
thiazol
orang
demonstr
hemolysi
day
compar
hemolysi
untreat
control
chang
atp
level
storag
compar
untreat
control
twoto
threefold
increas
potassium
leakag
thiazol
orangetr
rbc
compar
untreat
control
unillumin
rbc
control
contain
thiazol
orang
hemolysi
day
suggest
observ
hemolysi
may
due
presenc
thiazol
orang
rather
photoinduc
hemolysi
futur
develop
thiazol
orang
rbc
photoinactiv
agent
requir
toxicolog
scaleup
vivo
studi
blue
light
inactiv
pathogen
platelet
plasma
pilot
studymichel
maclean
phd
antimicrobi
properti
violetblu
light
research
area
gain
increas
promin
due
inher
properti
visibl
light
wavelength
research
initi
investig
potenti
develop
novel
altern
prt
workshop
present
provid
overview
pilot
studi
begun
evalu
antimicrobi
capabl
compat
violetblu
light
decontamin
blood
transfus
compon
recent
studi
demonstr
applic
violetblu
light
safe
continu
environment
decontamin
potenti
wound
decontamin
antimicrobi
applic
made
possibl
due
safeti
advantag
nonuv
light
wavelength
unlik
uv
light
induc
direct
dnabas
damag
andor
oxid
damag
expos
microbi
cell
depend
exact
uv
wavelength
use
inactiv
violetblu
light
involv
excit
endogen
photosensit
porphyrin
molecul
found
within
expos
microbi
cell
although
less
germicid
effici
research
demonstr
lowerenergi
violetblu
photon
particularli
suit
decontamin
sensit
blood
compon
potenti
oper
advantag
recent
studi
demonstr
antimicrobi
potenti
light
decontamin
key
bacteri
pathogen
blood
plasma
complet
reduct
staphylococcu
aureu
plasma
use
dose
approxim
jcm
importantli
antivir
potenti
also
demonstr
plasma
success
reduct
caliciviru
jcm
light
exposur
major
find
demonstr
studi
higher
penetr
light
photon
facilit
decontamin
prebag
transfus
product
result
show
signific
antimicrobi
efficaci
within
seal
plasma
transfus
bag
approxim
inactiv
aureu
contamin
plasma
achiev
use
low
irradi
light
dose
jcm
similar
antimicrobi
result
present
demonstr
success
decontamin
prebag
plt
suspens
compar
dose
level
use
plasma
prt
crucial
question
must
answer
whether
antimicrobi
efficaci
impart
neglig
andor
minim
effect
qualiti
blood
compon
result
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
western
blot
analysi
present
highlight
potenti
safe
treatment
blood
plasma
need
determin
upper
lower
threshold
treatment
level
would
facilit
decontamin
retain
plasma
plt
integr
regard
plt
evalu
vivo
recoveri
lighttreat
mwcm
hr
plt
murin
model
demonstr
differ
nontreat
plt
result
encourag
howev
investig
need
impact
dose
deliveri
high
irradi
light
deliv
rapid
exposur
period
compar
low
irradi
light
longer
exposur
influenc
optim
treatment
condit
blood
compon
discuss
highlight
potenti
technolog
util
rapid
treatment
storag
plt
plasma
incorpor
standard
storag
condit
plt
aim
extend
shelf
life
sensit
compon
abil
directli
treat
prebag
plasma
plt
blood
product
use
light
exposur
without
addit
photosensit
molecul
highli
desir
would
elimin
requir
addit
process
stage
need
prt
passag
equip
remov
chemic
addit
thu
reduc
crosscontamin
risk
also
potenti
reduc
process
time
thu
research
expand
understand
compat
technolog
blood
transfus
product
warrant
pathogen
reduct
blood
product
refriger
use
pathogen
reduct
technologycol
andrew
p
cap
md
phd
dod
invest
signific
resourc
develop
prt
improv
safeti
blood
transfus
battlefield
addit
need
reduc
risk
bacteri
contamin
associ
room
temperatur
storag
plt
uniqu
challeng
combat
casualti
care
includ
need
collect
wb
plt
remot
deploy
environ
transfus
product
avail
transfusiontransmit
diseas
test
result
risk
inher
emerg
blood
transfus
magnifi
donor
exposur
endem
diseas
malaria
potenti
biowarfar
agent
possibl
myelosuppress
radiat
exposur
battlefield
could
requir
inactiv
wbc
blood
product
reduc
risk
tagvhd
prt
wb
plt
urgent
need
support
militari
oper
addit
invest
technolog
use
variou
photosensit
uv
light
damag
nucleic
acid
pathogen
wbc
dod
pursu
altern
blood
storag
approach
reduc
infecti
risk
transfus
also
increas
avail
plt
sinc
current
room
temperatur
storag
practic
limit
shelf
life
day
refriger
demonstr
significantli
reduc
bacteri
growth
well
reduc
metabol
activ
plt
storag
preserv
hemostat
function
refriger
plt
retain
signific
capac
adher
collagen
shear
aggreg
releas
granul
catalyz
thrombin
gener
contract
clot
day
refriger
caus
partial
activ
plt
lead
desialyl
membran
protein
clearanc
circul
day
vivo
nevertheless
random
trial
cardiac
surgeri
patient
refriger
plt
store
day
perform
compar
standardofcar
plt
store
less
km
reddoch
cardena
cap
unpublish
plt
refriger
either
plasma
pa
preliminari
result
suggest
prttreat
plt
also
refriger
without
loss
hemostat
function
refriger
thu
offer
extra
layer
protect
bacteri
pathogen
addit
prt
also
opportun
extend
shelf
life
avail
preserv
essenti
contribut
plt
bleed
control
note
refriger
wb
contain
activ
plt
shown
maintain
consider
hemostat
function
entir
shelf
life
wb
day
dod
also
support
develop
altern
storag
modal
plt
cryopreserv
lyophil
technolog
offer
extend
storag
time
year
bacteri
pathogen
risk
reduct
could
combin
prt
clinic
safeti
efficaci
product
establish
refriger
without
prt
offer
practic
way
improv
plt
product
safeti
avail
wb
prt
remain
import
capabl
gap
us
militari
technolog
use
riboflavin
uv
light
shown
yield
product
preserv
hemostat
function
inactiv
ebola
viru
among
pathogen
reduc
transfusiontransmit
malaria
technolog
phase
iii
trial
success
develop
wb
prt
landmark
achiev
histori
transfus
medicin
benefit
civilian
militari
patient
comprehens
confer
prt
organ
fda
present
current
state
art
rais
sever
question
whose
answer
drive
futur
develop
clinic
implement
prt
although
follow
list
mean
allinclus
repres
recurr
theme
area
consid
confer
need
address
go
forward
issu
import
blood
safeti
pathogen
kill
vitro
cell
kill
measur
correl
clinic
efficaci
reader
remind
aim
trial
ghana
show
malari
prevent
infecti
load
greater
predict
capac
mirasol
system
review
comprehens
topic
publish
transfus
although
leukoreduct
significantli
reduc
alloimmun
patient
acut
leukemia
problem
alloimmun
refractori
plt
elimin
involv
wbc
febril
reaction
trali
effect
prt
procoagul
prothrombot
constitu
balanc
patient
prt
use
prepar
pool
plasma
product
reduc
infect
risk
take
advantag
abil
larg
pool
plasma
reduc
transfus
complic
allerg
reaction
abo
antibodyinduc
hemolysi
hypocoagul
due
variabl
content
coagul
constitu
singl
bag
recov
plasma
contain
addit
requir
prepar
prt
treat
wb
use
plasma
fraction
damag
rbc
current
prt
system
limit
new
process
develop
addit
manufactur
step
prt
process
affect
immunehematolog
test
procedur
addit
prt
reopen
age
blood
storag
controversi
unansw
question
realli
need
blood
storag
day
could
blood
transfus
system
unit
state
handl
shorter
storag
limit
requir
prttreat
rbc
fda
adopt
guidelin
industri
would
allow
enhanc
blood
storag
solut
use
prt
licens
implement
would
cost
sensit
much
new
knowledg
rbc
storag
would
need
appli
applic
licensur
prt
rbc
recoveri
surviv
hemolysi
major
criteria
licensur
b
fda
work
blood
center
increas
effici
modifi
blood
process
procedur
elimin
redund
test
donor
histori
c
cooper
effort
result
prt
compon
hospit
view
costeffect
worthi
increas
expens
guidelin
requir
becom
burdensom
ever
abl
take
advantag
clinic
oper
advantag
prt
improv
patient
care
